NCT01572649 - Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

Lixisenatide (AVE0010)

"Pharmaceutical form:Solution for injection~Route of administration: subcutaneous"

DRUG

Placebo

"Pharmaceutical form:Solution for injection~Route of administration: subcutaneous"

Trial Locations (6)

Investigational Site Number 710002, Cape Town

Investigational Site Number 840003, Louisville

Investigational Site Number 840001, Overland Park

Investigational Site Number 484001, Puebla City

Investigational Site Number 840005, Chula Vista

Investigational Site Number 826001, Leeds